Post by Brunella Lupano

Novartis announced a significant #workforce #reduction of 322 positions at its U.S. headquarters in East Hanover, New Jersey, marking its fourth round of corporate downsizing this year. The drugmaker filed a state WARN notice detailing that these #staff #cuts will take effect on October 2, 2026. This latest wave brings the total number of planned #job #eliminations at the East Hanover campus to 572 employees for the year.  The sweeping structural transformations are primarily driven by upcoming patent cliffs and strategic realignments across several global business units. Impacted Divisions and Role Reductions The recent operational adjustments affect multiple specialized divisions within the organization:  #Commercial #Teams: The latest cuts specifically reshape field sales, marketing, and patient support networks to boost localized market efficiency. #Specialized #Sales: Previous 2026 waves downsized field teams across Oncology, Neuroscience, Rheumatology, and Dermatology. Rare Disease #Units: A March wave eliminated 114 positions specifically targeting rare and ultra-rare medicine commercial teams. #Biomedical #Research: 76 roles were scaled back within the flagship research arm during May. Key Strategic Drivers The Patent Cliff: #Novartis is aggressively managing commercial revenue drops from losing exclusivity on major blockbusters. Sales for its prominent heart failure medicine, Entresto, tumbled to $1.3 #billion in Q1 2026 compared to $2.3 #billion in Q1 2025. Additional 2026 patent expirations include the leukemia drug Tasigna and platelet-booster Promacta.  Simplified #Operating #Model: The #layoffs fall under a broader multi-year global restructuring initiative launched back in 2022 to combine separate oncology and pharmaceutical divisions into a centralized Innovative Medicines model. The company expects to phase out roughly 8,000 #jobs #worldwide. Global Facilities #Closures Wehr, #Germany: Separate from the U.S. commercial changes, Novartis announced it will entirely shutter its manufacturing facility in Wehr by the end of 2028, cutting 220 jobs due to a lack of competitiveness in traditional solid oral dosage forms.  Basel, #Switzerland: The company remains on track with separate ongoing site restructurings to optimize sterile packaging lines, affecting up to 550 positions through 2027.